|
DNA variations signal lupus risk
January 21, 20089 variants helped to identify those who had up to twice the risk of getting lupus
BIRMINGHAM, Ala. - Scientists have pinpointed a set of common variations in human DNA that signal a higher risk for lupus in women who carry them. Some of these variations are more common in relatives of lupus patients, which may help future studies examining whether lupus is more prevalent among certain racial and ethnic groups, according to a new study.
Also, the findings point to various drug targets important to the search for cutting-edge lupus treatments, according to an international consortium of genetics researchers that includes scientists at the University of Alabama at Birmingham (UAB).
"Building on this finding we hope to identify those at highest risk of lupus, diagnose the disease earlier and hopefully find a cure," said Robert Kimberly, M.D., a professor of medicine in the UAB Division of Clinical Immunology and Rheumatology and co-author on the new study.
The findings are published in the journal Nature Genetics.
The study, the largest of its kind to date, is the work of the International Consortium for Systemic Lupus Erythematosus (SLEGEN), of which UAB is a member. SLE is the medical term for systemic lupus erythematosus, a common form of the disease.
Looking at the genomes of 6,728 people, the researchers found the variations located on various chromosomes in women of European ancestry. The variations may be linked to as many as 67 percent of all lupus cases in women, the study authors write.
"These findings underscore that numerous genes, which are often immune-function related, contribute to the risk of developing lupus," said Carl D. Langefeld, Ph.D., of Wake Forest University School of Medicine in Winston-Salem, N.C., the senior author on the SLEGEN study.
The Lupus Foundation of America estimates 1.5 million to 2 million Americans have a form of lupus, but the actual number may be higher. More than 90 percent of people with lupus are women and lupus rates are higher in African-American, Latino, Asian and Native American women than in women of other races and ethnicities.
Systemic lupus is a chronic inflammatory disease that can involve many organs, and often strikes the joints, kidneys, heart, lungs brain and the blood. The interaction of genetic variants and environmental factors are thought to contribute lupus susceptibility and severity, so the variants are a diagnostic tool and not a confirmation of disease.
While there is no cure for lupus, early diagnosis and proper medical treatment can significantly reduce inflammation, pain and stop future complications.
In the Nature Genetics study, the nine DNA variants helped to identify those who had up to twice the risk of getting lupus compared to those who did not have the variants, the study authors said.
"In addition to the drug targets, this study will help in the understanding of the causes of lupus and in the development of new genetic tests to find those most at risk for the disease," said Jeffrey Edberg, Ph.D., an associate professor of medicine in the UAB Division of Clinical Immunology and Rheumatology and co-author on the study.
Using the data from the study, UAB researchers and their SLEGEN collaborators are developing further studies to determine if the same gene variants signal higher lupus risks in certain ethnic or racial groups. Also, the scientists are examining how these genetic pathways contribute to developing lupus.
The UAB research team included scientists from the departments of Medicine, Epidemiology and Biostatistics. The consortium includes investigators from the Oklahoma Medical Research Foundation in Oklahoma City, Wake Forest University, the University of Minnesota in Minneapolis, the University of California at San Francisco, the University of California at Los Angeles, the University of Southern California in Los Angeles, the Imperial College London and the University of Uppsala in Sweden.
Funding for the study came from the Alliance for Lupus Research, the National Institute of Arthritis, Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases.
"We are hopeful this information will lead to new and better treatment possibilities and, eventually, a cure for lupus," said Barbara Boyts, president of the Alliance for Lupus Research.
University of Alabama at Birmingham
"Building on this finding we hope to identify those at highest risk of lupus, diagnose the disease earlier and hopefully find a cure," said Robert Kimberly, M.D., a professor of medicine in the UAB Division of Clinical Immunology and Rheumatology and co-author on the new study.
The findings are published in the journal Nature Genetics.
The study, the largest of its kind to date, is the work of the International Consortium for Systemic Lupus Erythematosus (SLEGEN), of which UAB is a member. SLE is the medical term for systemic lupus erythematosus, a common form of the disease.
Looking at the genomes of 6,728 people, the researchers found the variations located on various chromosomes in women of European ancestry. The variations may be linked to as many as 67 percent of all lupus cases in women, the study authors write.
"These findings underscore that numerous genes, which are often immune-function related, contribute to the risk of developing lupus," said Carl D. Langefeld, Ph.D., of Wake Forest University School of Medicine in Winston-Salem, N.C., the senior author on the SLEGEN study.
The Lupus Foundation of America estimates 1.5 million to 2 million Americans have a form of lupus, but the actual number may be higher. More than 90 percent of people with lupus are women and lupus rates are higher in African-American, Latino, Asian and Native American women than in women of other races and ethnicities.
Systemic lupus is a chronic inflammatory disease that can involve many organs, and often strikes the joints, kidneys, heart, lungs brain and the blood. The interaction of genetic variants and environmental factors are thought to contribute lupus susceptibility and severity, so the variants are a diagnostic tool and not a confirmation of disease.
While there is no cure for lupus, early diagnosis and proper medical treatment can significantly reduce inflammation, pain and stop future complications.
In the Nature Genetics study, the nine DNA variants helped to identify those who had up to twice the risk of getting lupus compared to those who did not have the variants, the study authors said.
"In addition to the drug targets, this study will help in the understanding of the causes of lupus and in the development of new genetic tests to find those most at risk for the disease," said Jeffrey Edberg, Ph.D., an associate professor of medicine in the UAB Division of Clinical Immunology and Rheumatology and co-author on the study.
Using the data from the study, UAB researchers and their SLEGEN collaborators are developing further studies to determine if the same gene variants signal higher lupus risks in certain ethnic or racial groups. Also, the scientists are examining how these genetic pathways contribute to developing lupus.
The UAB research team included scientists from the departments of Medicine, Epidemiology and Biostatistics. The consortium includes investigators from the Oklahoma Medical Research Foundation in Oklahoma City, Wake Forest University, the University of Minnesota in Minneapolis, the University of California at San Francisco, the University of California at Los Angeles, the University of Southern California in Los Angeles, the Imperial College London and the University of Uppsala in Sweden.
Funding for the study came from the Alliance for Lupus Research, the National Institute of Arthritis, Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases.
"We are hopeful this information will lead to new and better treatment possibilities and, eventually, a cure for lupus," said Barbara Boyts, president of the Alliance for Lupus Research.
University of Alabama at Birmingham
Lupus News and Current Lupus Events RSS'Multi-target' immune therapy improves outcomes of severe lupus nephritis
A new treatment using a combination of drugs targeting different parts of the immune system improves the recovery rate for patients with severe lupus involving the kidneys, according to a report in the October Journal of the American Society of Nephrology (JASN).
Specific location of the TRAF1/C5 gene associated with multiple autoimmune diseases
The TRAF1/C5 locus on chromosome 9 has been revealed to play a role in multiple autoimmune diseases including type 1 diabetes and systemic lupus erythematosus (SLE).
Ovarian function and fertility preserved in women with severe systemic lupus erythematosus
Ovarian function can be preserved and disease activity controlled in women with severe systemic lupus erythematosus (SLE) when treated with a 6-month course of cyclophosphamide (CYC), a chemotherapy drug, followed by the immunosuppressant mycophenolate mofetil (MMF).
Lupus more severe in patients with Southern European ancestry
ystemic lupus erythematosus (SLE) patients with a higher percentage of ancestry from southern Europe have more severe disease manifestations, according to new research presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.
'HiCy' drug regimen reverses ms symptoms in selected patients
A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and may even restore neurological function lost to the disease, Johns Hopkins researchers report.
Abnormal 'editing' of gene messages may be a cause of lupus
Researchers at Wake Forest University have uncovered evidence that the abnormal "editing" of gene messages in a type of white blood cell may be behind the development of lupus.
Adding epratuzumab to standard therapy
Adding a second monoclonal antibody drug to chemotherapy looks promising for treatment of diffuse large B-cell lymphoma.
UNH Glycomics Center Helps Identify Sugar Linkage That Could Lead To Better Treatment For Autoimmune Diseases
Researchers at the University of New Hampshire Glycomics Center have helped identify a specific carbohydrate structure that confers anti-inflammatory activity to a glycoprotein antibody that could lead to improved treatment of autoimmune diseases like lupus or rheumatoid arthritis.
St. Jude study shows how T cell's machinery dials down autoimmunity
A St. Jude Children's Research Hospital study shows that T cells, the body's master immune regulators, do not use simple on/off switches to govern the cellular machinery that regulates their development and function. Rather, they possess sophisticated molecular controls that enable them to adjust their function with exquisite precision.
Genes for common heart condition and kidney problem identified
A gene that can cause the heart to become enlarged, greatly increasing the risk of heart attacks and heart failure, is identified today in a new study.
More Lupus News Articles
| © 2008 BrightSurf.com |